A Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare, an independent specialty pharmacy focused on rare diseases, from Nautic Partners, General Atlantic, and The Vistria Group. Nautic Partners and PANTHERx management will remain significant shareholders.
PANTHERx dispenses medications for rare diseases and supports patients, prescribers, and drugmakers in navigating complex therapy programs, helping patients access and stay on treatment.Founded in a Pittsburgh garage in 2011, the company is licensed in all 50 states. Bansi Nagji continues as chief executive officer. The transaction is expected to close in the coming months.
Warburg Pincus, founded in 1966 and headquartered in New York, is a global growth investor with more than $105 billion in assets under management. T.J. Carella, managing director and head of healthcare, and Adam Krainson, a managing director, led the transaction for the firm. Nautic Partners, a middle-market private equity firm based in Providence, Rhode Island, focuses on healthcare, industrials, and services and has completed more than 165 platform transactions over its 40-year history.
J.P. Morgan Securities served as financial advisor to Warburg Pincus, with Centerview Partners and Goldman Sachs advising PANTHERx. Cleary Gottlieb provided legal counsel to Warburg Pincus and Ropes & Gray to PANTHERx.
